1Ferrari E,Benhamou M,Cerboni P,et al. Coronary syndromes following aspirin withdrawal:a special risk for late stent thrombosis[J]. J Am Coil Cardiol,2005,45(3):456-459.
2Njaman W,Miyauchi K,Kasai T,et al. Impact of aspirin treatment on long-term outcome (over lOyears) after percutaneous coronary intervention[ J]. lnt Heart J, 2006,47 ( 1 ) : 37-45.
3Mehta SR,Yusuf S,Peters RJ,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:The pci-cure study[J]. Lancet,2001,358(9281) :527-533.
4Jolly SS,Pogue J,Haladyn K,et al. Effects of aspirin dose on is- chaemie events and bleeding after percutaneous coronary inter- vention: Insights from the pci-cure study [J]. European Heart journal, 2009,30( 1 ) : 900-907.
5Steinhubl S,Berger P,Mann J,et al. Early and sustained dual o- ral antiplatelet therapy following percutaneous coronary inter- vention [ J ]. JAMA, 2002,288 (19) : 2411-2420.
6Karvouni E,Katritsis DG, Ioannidis JP. Intravenous glycoprotein lI b/I[I a receptor antagonists reduce mortality after percutaneous coronary interventions[J~. J Am Coil Cardiol,2003,41 ( 1 ) :26-32.
7Crnz-Gonzalez I,Sanchez-Ledesma M,Baron SJ,et al. Efficacy and safety of argatroban with or without glycoprotein 1I b/lll a inhibitor in patients with heparin induced thrombocytopenia un- dergoing percutaneous coronary intervention for acute coronary syndrome ~J ]. J Thromb Thrombolys, 2008,25 (2) : 214-218.
8Zhang ZF,Foster JK,Kohn P,et al. Reduced 6-month resource use and costs associated with cilostazol in patients after success- ful coronary stent implantation:results from the Cilostazol for RESTenosis (CREST) trial[Jl. Am Heart J,2006,152(4):770- 776.
9Chew DP,Lincoff AM,Gurm H,et al. Bivalirudin versus heparin and glycoprotein l] b/m a inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the replace-2 trial)[J]. Am J Cardiol,2005,95 (5) :581-585.
10Lamberts M,Gislason GH, Olesen JB,et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention[Jl. J Am Call Cardiol,2013,62 (11):981-989.
8Lip GY, Blann A. von Willebrand faetor: a marker of endothelial dysfunction in vascular disorders [ J]. Cardiovasc Res, 1997, 34 (2) : 255 - 265.
9Ghaisas NK, Shahi CN, Foley B, et al. Elevated levels of circulating soluble adhesion molecules in peripheral blood of patient with unstable angina [ J]. Am J Cardiol, 1997, 80 (5) : 617 -619.
10Zemlianskaia OA, Panchenko EP, Samko AN, et al. Matrixmetalloproteinases, C -reactive protein, and markers of thrombinemia in patients with stable angina and restenoses after percutaneous coronary interventions [ J]~ Kardiologiia, 2004, 44 (1): 4-12.
